Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate

Abstract

The use of plasma‐derived coagulation factor concentrates has been marked by the transmission of viral agents. Infusions of factor IX complex concentrates have been additionally complicated by inappropriate thrombosis. Use of these concentrates in the neonate, in those with liver disease, and in surgical patients results in increased risk for this complication. Twenty patients have been infused with a purified coagulation factor IX concentrate for fall‐off and recovery studies. A two‐compartment model indicated an initial phase half‐life of 4.06 ± 2.86 hr and a β phase half‐life of 20.0 ± 3.8 hr following the administration of AlphaNine®, Coagulation Factor IX (Human). In vivo recovery was 62.7% ± 13.8%, with an average factor IX coagulant level of 73% ± 16% at 15 min after the infusion of a mean dose of 45 U/kg. Thirteen previously transfused patients with hemophilia B underwent major orthopedic or general or dental surgery using this purified factor IX. Operative outcomes were excellent in all patients. No excessive bleeding was noted. There was no laboratory or clinical evidence for a disseminated intravascular coagulopathy. The excellent surgical outcomes observed in this multitransfused group with biochemical evidence for active liver disease demonstrates the utility and safety of a purified coagulation factor IX concentrate.